Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on May 20, 2024. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements. Note: The input metadata referenced "Insight Molecular Diagnostics Inc.," but the filing text explicitly identifies the registrant as Oncocyte Corporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of executive compensation terms.
Material Changes
The primary material change is the execution of a new employment agreement with Ekkehard Schütz, M.D., Ph.D., the Company's Chief Science Officer, effective May 20, 2024. This agreement supersedes and replaces a previous Managing Director Service Agreement held with the Company's German subsidiary, Chronix Biomedical GmbH.
Compensation and Contract Terms
- Term: Four years from the Effective Date, or until earlier termination.
- Base Salary: $351,525.20 annually.
- Annual Bonus: Eligible for a cash bonus equal to 50% of the Base Salary.
- Termination Provisions: In the event of termination without Cause or resignation for Good Reason, Dr. Schütz is entitled to:
- Accrued but unpaid Base Salary and vacation time.
- Severance equal to twelve months of Base Salary.
- A pro-rated portion of the Annual Bonus.
- Up to twelve months of continued group health plan participation.
- Accelerated vesting of the next tranche of time-based equity awards.
- Accelerated time vesting of performance-based equity awards that are performance-vested as of the termination date.
- Other Provisions: Includes standard cooperation, non-disparagement, non-publicity, general release, and clawback provisions.
Investor Verification Checklist
- Verify the full text of the Employment Agreement when filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2024.
- Confirm the definitions of "Cause" and "Good Reason" within the agreement to understand the specific triggers for severance.
- Review the Company's existing equity award plans to assess the impact of the accelerated vesting provisions on dilution.
- Monitor future filings for any changes to the German subsidiary's operations following the transition of Dr. Schütz's contract.